Literature DB >> 35239536

Extracorporeal Membrane Oxygenation as a Bridge to Surgical Repair of Postinfarct Ventricular Septal Defect.

Atsuo Doi1, Justin C Negri, Silvana F Marasco, Julian H Gooi, Adam Zimmet, Vincent A Pellegrino, Vinodh B Nanjayya, Steve A McGloughlin, David C McGiffin.   

Abstract

Postinfarct ventricular septal defect (PIVSD) is associated with high mortality and the management of these patients has been a challenge with little improvement in outcomes. We commenced a protocol of veno-arterial extracorporeal membrane oxygenation (VA ECMO) for those patients who present in cardiogenic shock with the aim to improve end-organ function before definitive surgical repair to reduce postoperative mortality. This study reviewed the results of this strategy. This was a single-center, retrospective review of all patients who were admitted to our institution with PIVSD in cardiogenic shock from September 2015 to November 2019. Clinical and investigative data were evaluated. Eight patients were referred with PIVSD during this period in cardiogenic shock. One patient had an anterior PIVSD and the other seven had inferior PIVSD. Six patients underwent surgical repair at a median (interquartile range, IQR) of 7 (5-8) days after initiation of VA ECMO. Two patients did not undergo surgical repair. Five patients survived after surgery and one patient died postoperatively due to multiorgan failure. Preoperative use of VA ECMO is a feasible strategy for PIVSD and may improve the results of repair.
Copyright © 2022 by the American Society for Artificial Internal Organs.

Entities:  

Year:  2022        PMID: 35239536     DOI: 10.1097/MAT.0000000000001664

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  1 in total

Review 1.  ECMO and Impella Support Strategies as a Bridge to Surgical Repair of Post-Infarction Ventricular Septal Rupture.

Authors:  Garrett Coyan; Neesha Anand; Mahnoor Imran; Hernando Gomez; Raj Ramanan; Holt Murray; Saurabh Sanon; Pyongsoo Yoon; David Kaczorowski; Johannes Bonatti
Journal:  Medicina (Kaunas)       Date:  2022-04-28       Impact factor: 2.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.